NCT03791112View on ClinicalTrials.gov

A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Cancer
Interventions
DRUG

BPI-16350

BPI-16350 capsules administered orally

Trial Locations (1)

311100

Betta Pharmaceuticals Co., Hangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY